DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

Phase 1 Completed 22 enrolled Medicines for Malaria Venture Institute of Tropical Medicine, University of Tuebingen · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Study to evaluate the efficacy of DSM265 as a causal prophylactic in a standardized and validated Human Challenge model using direct venous inoculation of aseptic, purified, cryopreserved, vialed Plasmodium falciparum sporozoites.

Timeline

Start: 2015-10
Primary completion: 2016-04
Completion: 2016-04

Publications

Results Sulyok M, Ruckle T, Roth A, Murbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibanez J, Sulyok Z, Held J, Gebru T, Granados P, Bruckner S, Nguetse C, Mengue J, Lalremruata A, Sim BKL, Hoffman SL, Mohrle JJ, Kremsner PG, Mordmuller B. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017 Jun;17(6):636-644. doi: 10.1016/S1473-3099(17)30139-1. Epub 2017 Mar 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Atovaquone	Small molecule	250 mg	Oral
Subject	DSM265	Small molecule	400 mg	Oral
Comparator	Proguanil	Small molecule	100 mg	Oral

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

Summary

Timeline

Publications

Drugs

Indications